Literature DB >> 22315332

Preclinical disposition of GDC-0973 and prospective and retrospective analysis of human dose and efficacy predictions.

Edna F Choo1, Marcia Belvin, Jason Boggs, Yuzhong Deng, Klaus P Hoeflich, Justin Ly, Mark Merchant, Christine Orr, Emile Plise, Kirk Robarge, Jean F Martini, Robert Kassees, Ron G Aoyama, Atulkumar Ramaiya, Stuart H Johnston.   

Abstract

[3,4-Difluoro-2-(2-fluoro-4-iodo-phenylamino)-phenyl]-((S)-3-hydroxy-3-piperidin-2-yl-azetidin-1-yl)-methanone (GDC-0973) is a potent and highly selective inhibitor of mitogen-activated protein kinase(MAPK)/extracellular signal-regulated kinase (ERK) 1/2 (MEK1/2), a MAPK kinase that activates ERK1/2. The objectives of these studies were to characterize the disposition of GDC-0973 in preclinical species and to determine the relationship of GDC-0973 plasma concentrations to efficacy in Colo205 mouse xenograft models. The clearance (CL) of GDC-0973 was moderate in mouse (33.5 ml · min(-1) · kg(-1)), rat (37.9 ± 7.2 ml · min(-1) · kg(-1)), and monkey (29.6 ± 8.5 ml · min(-1) · kg(-1)). CL in dog was low (5.5 ± 0.3 ml · min(-1) · kg(-1)). The volume of distribution across species was large, 6-fold to 15-fold body water; half-lives ranged from 4 to 13 h. Protein binding in mouse, rat, dog, monkey, and human was high, with percentage unbound, 1 to 6%. GDC-0973-related radioactivity was rapidly and extensively distributed to tissues; however, low concentrations were observed in the brain. In rats and dogs, [(14)C]GDC-0973 was well absorbed (fraction absorbed, 70-80%). The majority of [(14)C]GDC-0973-related radioactivity was recovered in the bile of rat (74-81%) and dog (65%). The CL and volume of distribution of GDC-0973 in human, predicted by allometry, was 2.9 ml · min(-1) · kg(-1) and 9.9 l/kg, respectively. The predicted half-life was 39 h. To characterize the relationship between plasma concentration of GDC-0973 and tumor growth inhibition, pharmacokinetic-pharmacodynamic modeling was applied using an indirect response model. The KC(50) value for tumor growth inhibition in Colo205 xenografts was estimated to be 0.389 μM, and the predicted clinical efficacious dose was ∼10 mg. Taken together, these data are useful in assessing the disposition of GDC-0973, and where available, comparisons with human data were made.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22315332     DOI: 10.1124/dmd.111.043778

Source DB:  PubMed          Journal:  Drug Metab Dispos        ISSN: 0090-9556            Impact factor:   3.922


  14 in total

1.  Why Decreasing Lipophilicity Alone Is Often Not a Reliable Strategy for Extending IV Half-life.

Authors:  Fabio Broccatelli; Ignacio Aliagas; Hao Zheng
Journal:  ACS Med Chem Lett       Date:  2018-04-19       Impact factor: 4.345

2.  Combined MEK and BCL-2/XL Inhibition Is Effective in High-Grade Serous Ovarian Cancer Patient-Derived Xenograft Models and BIM Levels Are Predictive of Responsiveness.

Authors:  Claudia Iavarone; Ioannis K Zervantonakis; Laura M Selfors; Sangeetha Palakurthi; Joyce F Liu; Ronny Drapkin; Ursula A Matulonis; Dorothy Hallberg; Victor E Velculescu; Joel D Leverson; Deepak Sampath; Gordon B Mills; Joan S Brugge
Journal:  Mol Cancer Ther       Date:  2019-01-24       Impact factor: 6.261

Review 3.  Targeting RAS-ERK signalling in cancer: promises and challenges.

Authors:  Ahmed A Samatar; Poulikos I Poulikakos
Journal:  Nat Rev Drug Discov       Date:  2014-12       Impact factor: 84.694

Review 4.  The biology and clinical development of MEK inhibitors for cancer.

Authors:  Jason J Luke; Patrick A Ott; Geoffrey I Shapiro
Journal:  Drugs       Date:  2014-12       Impact factor: 9.546

5.  Characterization of Aripiprazole Uptake Transporter in the Blood-Brain Barrier Model hCMEC/D3 Cells by Targeted siRNA Screening.

Authors:  Moeno Kadoguchi; Hiroshi Arakawa; Ryokichi Honda; Kazuki Hotta; Yoshiyuki Shirasaka; Yoshiharu Deguchi; Ikumi Tamai
Journal:  Pharm Res       Date:  2022-03-21       Impact factor: 4.200

6.  Efficacy of intermittent combined RAF and MEK inhibition in a patient with concurrent BRAF- and NRAS-mutant malignancies.

Authors:  Omar Abdel-Wahab; Virginia M Klimek; Alisa A Gaskell; Agnes Viale; Donavan Cheng; Eunhee Kim; Raajit Rampal; Mark Bluth; James J Harding; Margaret K Callahan; Taha Merghoub; Michael F Berger; David B Solit; Neal Rosen; Ross L Levine; Paul B Chapman
Journal:  Cancer Discov       Date:  2014-03-03       Impact factor: 39.397

7.  Oncogenic RAS pathway activation promotes resistance to anti-VEGF therapy through G-CSF-induced neutrophil recruitment.

Authors:  Vernon T Phan; Xiumin Wu; Jason H Cheng; Rebecca X Sheng; Alicia S Chung; Guanglei Zhuang; Christopher Tran; Qinghua Song; Marcin Kowanetz; Amy Sambrone; Martha Tan; Y Gloria Meng; Erica L Jackson; Franklin V Peale; Melissa R Junttila; Napoleone Ferrara
Journal:  Proc Natl Acad Sci U S A       Date:  2013-03-25       Impact factor: 11.205

8.  A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors.

Authors:  Lee S Rosen; Patricia LoRusso; Wen Wee Ma; Jonathan W Goldman; Amy Weise; A Dimitrios Colevas; Alex Adjei; Salim Yazji; Angela Shen; Stuart Johnston; Hsin-Ju Hsieh; Iris T Chan; Branimir I Sikic
Journal:  Invest New Drugs       Date:  2016-07-16       Impact factor: 3.850

9.  Evaluation of Cytochrome P450 3A4-Mediated Drug-Drug Interaction Potential for Cobimetinib Using Physiologically Based Pharmacokinetic Modeling and Simulation.

Authors:  Nageshwar R Budha; Tao Ji; Luna Musib; Steve Eppler; Mark Dresser; Yuan Chen; Jin Y Jin
Journal:  Clin Pharmacokinet       Date:  2016-11       Impact factor: 6.447

Review 10.  MEK and the inhibitors: from bench to bedside.

Authors:  Akintunde Akinleye; Muhammad Furqan; Nikhil Mukhi; Pavan Ravella; Delong Liu
Journal:  J Hematol Oncol       Date:  2013-04-12       Impact factor: 17.388

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.